Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 8,671 shares at $72.00 ($624K) on 2026-03-10, disclosed to the SEC on 2026-03-12.
Open-market sale of $624k BBIO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |
| BBIO | SELL | 2025-11-14 | $3.4M | — | Filing → |